1027155-76-5 Usage
General Description
N-[4-(5-Aminobenzimidazol-2-yl)phenyl]benzamide is a chemical compound with the molecular formula C20H16N4O. It is a benzamide derivative that contains an aminobenzimidazolylphenyl group. N-[4-(5-AMinobenziMidazol-2-yl)phenyl]benzaMide is commonly used in pharmaceutical research and drug development due to its potential therapeutic properties. It has been studied for its potential antitumor and antiviral activities, as well as its ability to inhibit certain enzymes in the body. Additionally, N-[4-(5-Aminobenzimidazol-2-yl)phenyl]benzamide has shown potential as a fluorescent probe that can be used for detecting and imaging specific biological molecules. Overall, this compound has a wide range of potential applications in both medicine and scientific research.
Check Digit Verification of cas no
The CAS Registry Mumber 1027155-76-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,2,7,1,5 and 5 respectively; the second part has 2 digits, 7 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1027155-76:
(9*1)+(8*0)+(7*2)+(6*7)+(5*1)+(4*5)+(3*5)+(2*7)+(1*6)=125
125 % 10 = 5
So 1027155-76-5 is a valid CAS Registry Number.
1027155-76-5Relevant articles and documents
Substituted 2-phenyl-benzimidazole derivatives: novel compounds that suppress key markers of allergy
Richards, Mark L.,Lio, Shirley Cruz,Sinha, Anjana,Banie, Homayon,Thomas, Richard J.,Major, Michael,Tanji, Mark,Sircar, Jagadish C.
, p. 950 - 969 (2007/10/03)
The pharmacotherapy of allergy and asthma has traditionally focused on the effecter molecules of the allergic cascade, while neglecting targets that play an early role in their development. Reasoning that IgE is central to the expansion of atopic diseases, we identified and extended a novel family of 2-(substituted phenyl)-benzimidazole inhibitors of IgE response. Pharmacological activity depends on an intact phenylbenzimidazole-bis-amide backbone, and is optimized by the presence of lipophilic terminal groups composed of either bis cycloalkyl or combinations of aliphatic and halogen-substituted aromatic groups. These compounds also inhibit IL-4 and IL-5 responses in T cells and CD23 expression on B cells, with potencies that parallel their inhibition of IgE. The broad profile of these compounds thus underscores their potential for treating the multifarious pathology of asthma.